Help us evaluate an investigational drug for diabetic retinopathy by joining our study.

Our research study in people with an early stage of diabetic retinopathy (DR) is testing different doses of an investigational drug (a pill) to learn more about its safety and effects on vision.

Current treatments for diabetic retinopathy include laser treatments, microsurgery, and medication injected into the eye. The investigational drug tested in the CANBERRA study is a tablet that is taken orally. It works in a different way than available treatments for DR.


The study will last approximately one year and will require 8 to 10 clinic visits. You will be paid for study visits and reimbursed for travel costs.

Interested in joining the CANBERRA Study?

Contact us to learn more about the study and find out next steps for participating.

Give us a call +1 (888) 662-6728

Or send us an email:
global-roche-genentech-trials@gene.com

Study ID #BP41321

A Clinical Trial in Diabetic Retinopathy

Learn more about this study and find out if you are eligible to participate.
Learn more about the study